Diamedica Therapeutics Inc Stock Ownership - Who owns Diamedica Therapeutics?

Insider buying vs selling

Have Diamedica Therapeutics Inc insiders been buying or selling?
David J. WambekeChief Business Officer2023-04-10468,750$1.60
Randall Michael GiuffreDirector2023-01-0335,130$1.53
Amy L. BurroughsDirector2023-01-0317,156$1.53
Richard D. PilnikDirector2023-01-0355,555$1.53
Charles Pauling SembaDirector2023-01-0317,156$1.53
Randall Michael GiuffreDirector2022-12-0937,079$1.43
Randall Michael GiuffreDirector2022-12-0820,000$1.40
Randall Michael GiuffreDirector2022-12-0722,574$1.40
Randall Michael GiuffreDirector2022-12-062,300$1.35
Richard D. PilnikDirector2022-12-0535,000$1.39

1 of 2

DMAC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DMAC insiders and whales buy or sell their stock.

DMAC Shareholders

What type of owners hold Diamedica Therapeutics Inc stock?
Koch Thomas Von20.43%5,503,720$15.14MInsider
Zhenyu Xiao3.74%1,007,100$2.77MInsider
Vanguard Group Inc2.91%782,989$2.15MInstitution
David J. Wambeke1.74%468,750$1.29MInsider
Randall Michael Giuffre1.57%421,757$1.16MInsider
Jacob Asset Management Of New York LLC0.87%233,730$642.76kInstitution
Richard D. Pilnik0.78%209,882$577.18kInsider
Geode Capital Management LLC0.69%184,870$508.39kInstitution
Northern Trust Corp0.34%90,825$249.77kInstitution
Amy L. Burroughs0.27%73,288$201.54kInsider

1 of 3

DMAC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DMAC6.30%29.21%Net BuyingNet Buying
CRDF15.78%34.48%Net Buying
CLNN3.87%71.31%Net Buying
FBIO21.31%32.84%Net Buying

Diamedica Therapeutics Stock Ownership FAQ

Who owns Diamedica Therapeutics?

Diamedica Therapeutics (NASDAQ: DMAC) is owned by 6.30% institutional shareholders, 29.21% Diamedica Therapeutics insiders, and 64.49% retail investors. Koch Thomas Von is the largest individual Diamedica Therapeutics shareholder, owning 5.50M shares representing 20.43% of the company. Koch Thomas Von's Diamedica Therapeutics shares are currently valued at $15.14M.

If you're new to stock investing, here's how to buy Diamedica Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.